How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 11 Jul | 18 Jul | 25 Jul | 24 Aug | 28 Aug | 04 Sep | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 58.1 | 57.3 | 57.3 | 55.2 | 55.2 | 55.2 | -2.9 |
| Healthcare | 33.7 | 35.1 | 35.1 | 35.1 | 35.1 | 35.1 | +1.4 |
| Chemicals | 3.1 | 3.1 | 3.1 | 2.8 | 2.8 | 2.8 | -0.3 |
| Unclassified | · | · | · | 1.0 | 1.0 | 1.0 | 0.0 |
| Financial Services | 2.5 | 1.0 | 1.0 | 0.9 | 0.9 | 0.9 | -1.6 |
| Digital | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | -0.1 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 10.86% | 7 | 8 | 7 | 8 | 5 | — | +1.5% |
| DIVISLAB | Pharma | 10.35% | 9 | 8 | 1 | 4 | 1 | — | +38.4% |
| TORNTPHARM | Pharma | 9.38% | 7 | 8 | 5 | 4 | 1 | — | +7.0% |
| ASTERDM | Healthcare | 6.21% | 6 | 2 | 9 | 4 | 2 | — | -0.6% |
| MAXHEALTH | Healthcare | 5.86% | 1 | 9 | 6 | 5 | 6 | — | -6.0% |
| AJANTPHARM | Pharma | 5.20% | 8 | 10 | 1 | 3 | 3 | — | +13.9% |
| MANKIND | Pharma | 4.66% | 4 | 8 | 9 | 3 | 5 | — | -6.1% |
| LALPATHLAB | Healthcare | 4.05% | 7 | 8 | 7 | 5 | 3 | — | +18.6% |
| KIMS | Healthcare | 3.77% | 4 | 3 | 6 | 10 | 2 | — | -9.0% |
| RUBICON | Pharma | 3.68% | 7 | 8 | 5 | 4 | 1 | — | +43.6% |
| ABBOTINDIA | Pharma | 3.23% | 3 | 9 | — | 6 | 8 | — | -3.8% |
| NEULANDLAB | Healthcare | 3.03% | 8 | 10 | 7 | 4 | 1 | — | +30.4% |
| NAVINFLUOR | Chemicals | 2.81% | 9 | 10 | 4 | 8 | 1 | Leader | +20.9% |
| SAILIFE | Healthcare | 2.56% | 9 | 10 | 5 | 9 | 1 | Leader | +27.8% |
| CIPLA | Pharma | 2.39% | 4 | 3 | 6 | 4 | 7 | — | -3.9% |
| PFIZER | Healthcare | 2.25% | 5 | 7 | 1 | 8 | 7 | — | -2.9% |
| JLHL | Healthcare | 2.23% | 1 | 9 | 4 | 2 | 10 | — | -83.0% |
| ANTHEM | Pharma | 1.99% | 10 | 10 | 6 | 3 | 1 | Leader | +16.3% |
| MEDANTA | Healthcare | 1.83% | 8 | 9 | 5 | 4 | 2 | — | +13.1% |
| ZYDUSLIFE | Pharma | 1.35% | 9 | 10 | 10 | 2 | 8 | — | +1.9% |
| FORTIS | Healthcare | 1.28% | 4 | 8 | 5 | 5 | 6 | — | -12.4% |
| LUPIN | Pharma | 1.23% | 3 | 10 | 10 | 7 | 9 | — | -11.1% |
| ORCHPHARMA | Pharma | 0.91% | 7 | 1 | 4 | 10 | 2 | — | +8.0% |
| AGARWALEYE | Healthcare | 0.90% | 8 | 5 | 8 | 1 | 3 | — | +10.3% |
| ICICIGI | Financial Services | 0.89% | 1 | 6 | 4 | 6 | 8 | — | -18.5% |
| LENSKART | Healthcare | 0.68% | 10 | 1 | 6 | 4 | 1 | Leader | +31.9% |
| SAGILITY | Digital | 0.48% | 6 | 9 | 8 | 7 | 8 | — | +13.4% |
Performance · 1.7y
Over the last 1.7 years ₹100 in the fund grew to ₹122 (+22%), vs ₹99 for Nifty 500 (−1%) and ₹96 for Nifty 50 (−4%). Its relative-strength line ended at 127 vs Nifty 50 and 123 vs Nifty 500 — above 100, sustained outperformance.